^
    2d
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    8d
    Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Ruijin Hospital
    New P1/2 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Beqalzi (sonrotoclax)
    10d
    BGB-11417-108: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (clinicaltrials.gov)
    P1/2, N=258, Recruiting, BeOne Medicines | N=56 --> 258 | Trial completion date: Dec 2027 --> Nov 2032 | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2027 --> Nov 2029
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    13d
    A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, BeOne Medicines
    New P1 trial
    |
    Beqalzi (sonrotoclax)
    1m
    Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Canadian Cancer Trials Group | Initiation date: Mar 2026 --> Jun 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    1m
    A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Blincyto (blinatumomab) • Beqalzi (sonrotoclax)
    2ms
    BGB-11417-2001-IIT: Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • Beqalzi (sonrotoclax)
    2ms
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=500, Recruiting, BeOne Medicines | N=186 --> 500
    Enrollment change • Trial initiation date
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Beqalzi (sonrotoclax)
    2ms
    CaDAnCe-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=80, Recruiting, BeOne Medicines
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    2ms
    BGB-11417-304: A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Previously Untreated Chronic Lymphocytic Leukemia (2025-524366-21-00)
    P2/3, N=161, Not yet recruiting, BeOne Medicines I GmbH
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Beqalzi (sonrotoclax)
    2ms
    FLOURISH: Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    2ms
    The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Ruijin Hospital
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)